gem333
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 11, 2018 (NCT03516760)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03516760 | Phase 1 | Apr 11, 2018 | GCP-Service International Ltd. & Co. KG, GEMoaB Monoclonals GmbH, Technical University of Dresden |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GCP-Service International Ltd. & Co. KG | For profit | 1 | 0 | 1 | 2018 |
| GEMoaB Monoclonals GmbH | For profit | 1 | 1 | 1 | 2018 |
| Technical University of Dresden | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1